Thalidomide scandal
The thalidomide scandal represents a chilling chapter in medical history, revealing the catastrophic consequences of inadequate drug testing and regulation. Once hailed as a miracle drug, its widespread use led to tens of thousands of babies being born with severe birth defects globally, forever changing countless lives. This tragedy became a stark, undeniable catalyst for a global overhaul of pharmaceutical safety protocols, reminding us of the immense responsibility inherent in medical innovation. Thalidomide, initially marketed as a safe sedative and anti-nausea drug, caused devastating birth defects in over 10,000 babies worldwide due to insufficient safety testing on pregnant individuals. The global crisis exposed critical flaws in drug regulation, leading to a demand for rigorous efficacy and safety testing before any new medication could reach the market. The courageous actions of a few, notably Dr. Frances Oldham Kelsey in the U.S., prevented wider catastrophe by resisting immense pressure to approve the drug, highlighting the importance of scientific integrity.
AI Summary
The thalidomide scandal represents a chilling chapter in medical history, revealing the catastrophic consequences of inadequate drug testing and regulation. Once hailed as a miracle drug, its widespread use led to tens of thousands of babies being born with severe birth defects globally, forever changing countless lives. This tragedy became a stark, undeniable catalyst for a global overhaul of pharmaceutical safety protocols, reminding us of the immense responsibility inherent in medical innovation.
- Thalidomide, initially marketed as a safe sedative and anti-nausea drug, caused devastating birth defects in over 10,000 babies worldwide due to insufficient safety testing on pregnant individuals.
- The global crisis exposed critical flaws in drug regulation, leading to a demand for rigorous efficacy and safety testing before any new medication could reach the market.
- The courageous actions of a few, notably Dr. Frances Oldham Kelsey in the U.S., prevented wider catastrophe by resisting immense pressure to approve the drug, highlighting the importance of scientific integrity.
A Sedative with a Silent Shadow
In the mid-1950s, a new drug called thalidomide emerged, first developed by Swiss pharmaceutical company Ciba. It quickly gained popularity as a tranquilizer, then as a highly effective sedative that promised restful sleep without the dangers of barbiturates. Soon, it was marketed by the West German company Chemie Grünenthal under the trade name Contergan.
Grünenthal acquired the product in 1954 and, seeing its potential, expanded its applications. Beyond sleep, it was prescribed for anxiety, tension, and even morning sickness in pregnant women. Crucially, it was introduced without having been adequately tested for its effects on developing fetuses—a critical oversight that would have unimaginable consequences.
Between 1957 and 1961, thalidomide was prescribed to pregnant women in 46 countries, reaching across Europe, Australia, Canada, Japan, and parts of the United States. It was hailed as a safe solution for common pregnancy discomforts, with no one suspecting the silent threat it carried. This widespread distribution laid the groundwork for what would become one of the biggest anthropogenic medical disasters ever recorded.
The Unfolding Catastrophe
The devastating truth began to surface in 1961: thalidomide was causing severe birth defects. The total number of embryos affected is estimated at more than 10,000, and potentially up to 20,000. Tragically, approximately 40% of these infants died at or shortly after birth.
Those who survived often faced lifelong challenges. The drug caused a range of congenital defects including phocomelia—a severe shortening or absence of limbs—along with dysmelia, amelia, and other malformations affecting the eyes, ears, heart, and internal organs. The most common presentation was shortened limbs, with arms more frequently impacted.
The severity and location of the deformities depended on the precise timing of exposure during pregnancy. Taking thalidomide on day 20 could cause central brain damage, day 21 would affect the eyes, and day 22 the ears and face. Exposure on day 24 could damage arms, and legs could be affected up to day 28. If taken after 42 days of gestation, the fetus was typically not harmed.
Unmasking the Culprit
The link between thalidomide and birth defects was first suspected by individuals like Australian obstetrician William McBride and German pediatrician Widukind Lenz. Sister Pat Sparrow, a midwife under McBride's care, first observed a pattern of birth defects in babies whose mothers had taken the drug, prompting McBride to raise concerns.
Dr. Lenz, through meticulous scientific research in 1961, provided the crucial evidence proving the connection. This was further corroborated by animal tests conducted by George Somers in Britain, showing fetal abnormalities in rabbits, rats, and other species, unequivocally demonstrating thalidomide's teratogenic effects—its ability to cause birth defects.
A Heroine in the United States
While many countries approved thalidomide, the United States was largely spared a widespread catastrophe, thanks to the vigilance of one remarkable individual: Dr. Frances Oldham Kelsey. A pharmacologist at the U.S. Food and Drug Administration (FDA), she refused to approve the drug for market, demanding further safety studies.
Despite immense pressure from the Richardson-Merrell Pharmaceuticals Co. to approve thalidomide, Dr. Kelsey stood firm. Her scientific integrity and skepticism in the face of incomplete data prevented countless American children from suffering the same fate as those in other nations. Her courage made her a national hero.
For denying the application, President John F. Kennedy awarded Dr. Kelsey the President's Award for Distinguished Federal Civilian Service in 1962. Decades later, the FDA honored her legacy by establishing the annual Kelsey Award for outstanding staff contributions, a testament to her enduring impact on drug safety.
Even though thalidomide was not approved for sale in the U.S., it wasn't entirely absent. Over 2.5 million tablets were distributed to more than 1,000 physicians as part of a clinical testing program, reaching nearly 20,000 patients—including several hundred pregnant women. This led to at least 17 documented cases of thalidomide-associated deformities in the U.S. Cardiologist Helen B. Taussig also played a vital role, testifying before Congress in 1967 after witnessing the devastating effects firsthand in Germany, reinforcing the ban in the US and Europe.
A Global Reckoning
Across the globe, the response to the thalidomide crisis varied. In the UK, the drug was licensed in 1958 and withdrawn in 1961, affecting around 2,000 babies, with hundreds surviving to adulthood. After a long public campaign, a significant compensation settlement was reached with Distillers Company in 1968, though the fight for ongoing support continued for decades.
Spain faced a particularly grim reality, with thalidomide remaining widely available throughout the 1970s and potentially even into the 1980s. Poor state controls and Grünenthal's failure to warn Spanish doctors meant the government didn't even acknowledge the drug's importation until 2008. Hundreds of survivors in Spain continue to live with its devastating impact.
Canada also felt the impact, with thalidomide sold until 1962. The disaster here spurred the formation of the Society of Toxicology of Canada, separating toxicology from pharmacology to enhance research into chemical substance safety. Canadian survivors continue to campaign for comprehensive support, with some still struggling to receive adequate government compensation due to documentation requirements.
In Australia and New Zealand, victims like Lynette Rowe, born without limbs, led class action lawsuits against Grünenthal, resulting in significant out-of-court settlements in the millions for hundreds of survivors. Meanwhile, East Germany completely rejected thalidomide, with no known affected children born there, while West Germany faced delays in connecting the drug to the increase in birth defects.
Japan also counts approximately 300 survivors as of 2019, who report enduring high levels of worry and stress related to their future. In Austria, stricter prescription medication rules enforced by Ingeborg Eichler meant fewer affected children were born compared to other nations, highlighting the power of early regulatory action.
The Aftermath: Justice and Compensation
In 1968, a large criminal trial began in West Germany, charging several Grünenthal officials with negligent homicide and injury. Though the trial ended in 1970 without a finding of guilt after Grünenthal settled with victims, the company paid 100 million DM into a special foundation, supplemented by the West German government.
This foundation provided victims with one-time payments and monthly stipends, which have since been substantially raised and are now entirely government-funded. Decades later, in 2008, Grünenthal made another €50 million payment into the foundation, demonstrating the long tail of accountability for such a profound disaster.
In 2012, more than 50 years after the initial scandal, Grünenthal chief executive Harald F. Stock issued the company's first apology for producing the drug and remaining silent about its devastating birth defects. However, victim advocates widely criticized the apology as
insulting
and
too little, too late,
pointing to the company's continued refusal to directly compensate survivors and its claims that no one could have known the drug's harm, despite many red flags at the time.
A Legacy of Resilience and Reform
Despite their profound disabilities, many thalidomide survivors have lived extraordinary lives, becoming advocates, artists, and athletes. Figures like Canadian Paralympic gold medalist Josée Lake, musician Mat Fraser, and filmmaker Niko von Glasow have shared their stories, turning personal tragedy into powerful messages of resilience and awareness.
The thalidomide disaster became a powerful catalyst for sweeping changes in drug regulation worldwide. Countries introduced tougher rules for testing and licensing, such as the Kefauver Harris Amendment in the U.S., Directive 65/65/EEC1 in the E.U., and the Medicines Act 1968 in the UK. These reforms demanded rigorous proof of efficacy and the disclosure of all side effects, fundamentally reshaping how new drugs are brought to market.
In 2023, the Australian Government unveiled a national memorial site and issued a formal apology to those affected by thalidomide, acknowledging the
dark chapter
in their history. This act of remembrance serves as a permanent reminder of the lessons learned and the ongoing commitment to protecting public health from such preventable tragedies.
Article
Thalidomide scandal
Feet of a baby born to a mother who had taken thalidomide while pregnant
In the late 1950s and early 1960s, thalidomide was prescribed to women in 46 countries who were pregnant or who subsequently became pregnant, and consequently resulted in the "biggest anthropogenic medical disaster ever," with more than 10,000 children born with a range of severe deformities, such as phocomelia, as well as thousands of miscarriages.
Thalidomide was introduced in 1957 as a tranquilizer, and was later marketed by the West German pharmaceutical company Chemie Grünenthal under the trade name Contergan as a medication for anxiety, trouble sleeping, tension, and morning sickness. It was introduced as a sedative and medication for morning sickness without having been tested on pregnant women. While initially deemed to be safe in pregnancy, concerns regarding birth defects were noted in 1961, and the medication was removed from the market in Europe that year.
Development of thalidomide
Thalidomide scandal
Thalidomide was first developed as a tranquilizer by Swiss pharmaceutical company Ciba in 1953. In 1954, Ciba abandoned the product, and it was acquired by German pharmaceutical company Chemie Grünenthal. The company had been established by Hermann Wirtz Sr, a Nazi Party member, after World War II as a subsidiary of the family's Mäurer & Wirtz company. The company's initial aim was to develop antibiotics for which there was an urgent market need.
Birth defect crisis
Thalidomide scandal
The total number of embryos affected by the use of thalidomide during pregnancy is estimated at more than 10,000, and potentially up to 20,000; of these, approximately 40 percent died at or shortly after the time of birth. Those who survived had limb, eye, urinary tract, and heart defects. Its initial entry into the U.S. market was prevented by Frances Oldham Kelsey at the U.S. Food and Drug Administration (FDA). The birth defects of thalidomide led to the development of greater drug regulation and monitoring in many countries.
The severity and location of the deformities depended on how many days into the pregnancy the mother was before beginning treatment; thalidomide taken on the 20th day of pregnancy caused central brain damage, day 21 would damage the eyes, day 22 the ears and face, day 24 the arms, and leg damage would occur if taken up to day 28. Thalidomide did not damage the fetus if taken after 42 days' gestation.
United Kingdom
Artificial limbs made for an affected child in the 1960s by the Department of Health and Social Security's Limb Fitting Centre in Roehampton, London
In the UK, the drug was licensed in 1958 and withdrawn in 1961. Of the approximately 2,000 babies born with defects, around half died within a few months and 466 survived to at least 2010. In 1968, after a long campaign by The Sunday Times, a compensation settlement for the UK victims was reached with Distillers Company (now part of Diageo), which had distributed the drug in the UK. Distillers Biochemicals paid out approximately £28m in compensation following a legal battle.
The British Thalidomide Children's Trust was set up in 1973 as part of a £20 million legal settlement between Distillers Company and 429 children with thalidomide-related disabilities. In 1997, Diageo (formed by a merger between Grand Metropolitan and Guinness, who had taken over Distillers in 1990) made a long-term financial commitment to support the Thalidomide Trust and its beneficiaries. The UK government gave survivors a grant of £20 million, to be distributed through the Thalidomide Trust, in December 2009.
Spain
In Spain, thalidomide was widely available throughout the 1970s, and perhaps even into the 1980s. There were two reasons for this. First, state controls and safeguarding were poor; it was not until 2008 that the government even admitted the country had ever imported thalidomide. Second, Grünenthal failed to insist that its sister company in Madrid warn Spanish doctors, and permitted its sister company not to warn doctors of the defects. The Spanish advocacy group for victims of thalidomide estimates that in 2015, there were 250–300 living victims of thalidomide in Spain.
Australia and New Zealand
Australian obstetrician William McBride raised concern about thalidomide after a midwife called Sister Pat Sparrow first suspected the drug was causing birth defects in the babies of patients under McBride's care at Crown Street Women's Hospital in Sydney. German paediatrician Widukind Lenz, who also suspected the link, is credited with conducting the scientific research that proved thalidomide was causing birth defects in 1961. Further animal tests were conducted by George Somers, Chief Pharmacologist of Distillers Company in Britain, which showed fetal abnormalities in rabbits. Similar results were also published showing these effects in rats and other species.
Lynette Rowe, who was born without limbs, led an Australian class action lawsuit against the drug's manufacturer, Grünenthal, which fought to have the case heard in Germany. The Supreme Court of Victoria dismissed Grünenthal's application in 2012, and the case was heard in Australia. On 17 July 2012, Rowe was awarded an out-of-court settlement, believed to be in the millions of dollars and providing precedence for class action victims to receive further compensation. In February 2014, the Supreme Court of Victoria endorsed the settlement of $89 million AUD to 107 victims of the drug in Australia and New Zealand.
Germany
In East Germany, thalidomide was rejected by the Central Committee of Experts for the Drug Traffic in the GDR, and was never approved for use. There are no known thalidomide children born in East Germany. Meanwhile, in West Germany, it took some time before the increase in dysmelia at the end of the 1950s was connected with thalidomide. In 1958, Karl Beck, a former pediatric doctor in Bayreuth, wrote an article in a local newspaper claiming a relationship between nuclear weapons testing and cases of dysmelia in children. Based on this, FDP leader Erich Mende requested an official statement from the federal government. For statistical reasons, the main data series used to research dysmelia cases started by chance at the same time as the approval date for thalidomide. After the Nazi regime with its Law for the Prevention of Hereditarily Diseased Offspring used mandatory statistical monitoring to commit various crimes, western Germany had been very reluctant to monitor congenital disorders in a similarly strict way. The parliamentary report rejected any relation with radioactivity and the abnormal increase of dysmelia. Also the DFG research project installed after the Mende request was not helpful. The project was led by pathologist Franz Büchner, who ran the project to propagate his teratological theory. Büchner saw lack of healthy nutrition and behavior of the mothers as being more important than genetic reasons. Furthermore, it took a while to appoint a Surgeon General in Germany; the Federal Ministry of Health was not founded until 1962, some months after thalidomide was banned from the market. In West Germany approximately 2,500 children were born with birth defects from thalidomide.
Canada
Despite its severe side effects, thalidomide was sold in pharmacies in Canada until 1962. The effects of thalidomide increased fears regarding the safety of pharmaceutical drugs. The Society of Toxicology of Canada was formed after the effects of thalidomide were made public, focusing on toxicology as a discipline separate from pharmacology. The need for the testing and approval of the toxins in certain pharmaceutical drugs became more important after the disaster. The Society of Toxicology of Canada is responsible for the Conservation Environment Protection Act, focusing on researching the impact to human health of chemical substances. Thalidomide brought on changes in the way drugs are tested, what type of drugs are used during pregnancy, and increased the awareness of potential side effects of drugs.
According to Canadian news magazine programme W5, most, but not all, victims of thalidomide receive annual benefits as compensation from the Government of Canada. Excluded are those who cannot provide the documentation the government requires.
A group of 120 Canadian survivors formed the Thalidomide Victims Association of Canada, the goal of which is to prevent the approval of drugs that could be harmful to pregnant individuals and babies. The members from the thalidomide victims association were involved in the STEPS programme, which aimed to prevent teratogenicity.
United States
1962: FDA pharmacologist Frances Oldham Kelsey receives the President's Award for Distinguished Federal Civilian Service from President John F. Kennedy for blocking sale of thalidomide in the United States.
In the U.S., the FDA refused approval to market thalidomide, saying further studies were needed. This reduced the impact of thalidomide in American patients. The refusal was largely due to pharmacologist Frances Oldham Kelsey who withstood pressure from the Richardson-Merrell Pharmaceuticals Co. Although thalidomide was not approved for sale in the United States at the time, over 2.5 million tablets had been distributed to over 1,000 physicians during a clinical testing programme. It is estimated that nearly 20,000 patients, several hundred of whom were pregnant, were given the drug to help alleviate morning sickness or as a sedative, and at least 17 children were consequently born in the United States with thalidomide-associated deformities. While pregnant, children's television host Sherri Finkbine took thalidomide that her husband had purchased over-the-counter in Europe. When she learned that thalidomide was causing fetal deformities she wanted to abort her pregnancy, but the laws of Arizona allowed abortion only if the mother's life was in danger. Finkbine traveled to Sweden to have the abortion. Thalidomide was found to have deformed the fetus.
For denying the application despite the pressure from Richardson-Merrell Pharmaceuticals Co., Kelsey eventually received the President's Award for Distinguished Federal Civilian Service at a 1962 ceremony with President John F. Kennedy. In September 2010, the FDA honored Kelsey with the first Kelsey award, given annually to an FDA staff member. This came 50 years after Kelsey, then a new medical officer at the agency, first reviewed the application from the William S. Merrell Pharmaceuticals Company of Cincinnati.
Cardiologist Helen B. Taussig learned of the damaging effects of the drug thalidomide on newborns and in 1967, testified before Congress on this matter after a trip to Germany where she worked with infants with phocomelia (severe limb deformities). As a result of her efforts, thalidomide was banned in the United States and Europe.
Austria
Ingeborg Eichler, a member of the Austrian pharmaceutical admission conference, enforced restrictions on the sale of thalidomide (tradename Softenon) under the rules of prescription medication and as a result relatively few affected children were born in Austria and Switzerland.
Japan
Approximately 300 survivors of thalidomide were thought to be living in Japan as of 2019. Survivors reported "higher levels of worry and stress, especially in terms of the future".
Aftermath of scandal
Thalidomide scandal
Thalidomide Memorial in Cardiff, Wales
The numerous reports of malformations in babies brought about the awareness of the side effects of the drug on pregnant women. The birth defects caused by the drug thalidomide can range from moderate malformation to more severe forms. Possible birth defects include phocomelia, dysmelia, amelia, bone hypoplasticity, and other congenital defects affecting the ear, heart, or internal organs. Franks et al. looked at how the drug affected newborn babies, the severity of their deformities, and reviewed the drug in its early years. Webb in 1963 also reviewed the history of the drug and the different forms of birth defects it had caused. "The most common form of birth defects from thalidomide is shortened limbs, with the arms being more frequently affected. This syndrome is the presence of deformities of the long bones of the limbs resulting in shortening and other abnormalities."
Grünenthal criminal trial
In 1968, a large criminal trial began in West Germany, charging several Grünenthal officials with negligent homicide and injury. After Grünenthal settled with the victims in April 1970, the trial ended in December 1970 with no finding of guilt. As part of the settlement, Grünenthal paid 100 million DM into a special foundation; the West German government added 320 million DM. The foundation paid victims a one-time sum of 2,500–25,000 DM (depending on severity of disability) and a monthly stipend of 100–450 DM. The monthly stipends have since been raised substantially and are now paid entirely by the government (as the foundation had run out of money). Grünenthal paid another €50 million into the foundation in 2008.
On 31 August 2012, Grünenthal chief executive Harald F. Stock— who served as the chief executive officer of Grünenthal GmbH from January 2009 to May 28, 2013— apologized for the first time for producing the drug and remaining silent about the birth defects. At a ceremony, Stock unveiled a statue of a disabled child to symbolize those harmed by thalidomide and apologized for not trying to reach out to victims for over 50 years. At the time of the apology, there were between 5,000 and 6,000 people still living with Thalidomide-related birth defects. Victim advocates called the apology "insulting" and "too little, too late", and criticized the company for not compensating victims and for their claim that no one could have known the harm the drug caused, arguing that there were plenty of red flags at the time.
Australian National Memorial
On 13 November 2023, the Australian Government announced its intention to make a formal apology to people affected by thalidomide with the unveiling of a national memorial site. Prime Minister Anthony Albanese described the thalidomide tragedy as a "dark chapter" in Australian history, and Health Minister Mark Butler said, "While we cannot change the past or end the physical suffering, I hope these important next steps of recognition and apology will help heal some of the emotional wounds."
Notable cases
Thalidomide scandal
Niko von Glasow, German filmmaker
• Mercédes Benegbi, born with phocomelia of both arms, drove the successful campaign for compensation from her government for Canadians who were affected by thalidomide. • Mat Fraser, born with phocomelia of both arms, is an English rock musician, actor, writer and performance artist. He produced a 2002 television documentary, Born Freak, which looked at this historical tradition and its relevance to modern disabled performers. This work has become the subject of academic analysis in the field of disability studies. • Niko von Glasow, a thalidomide survivor, produced a documentary called NoBody's Perfect, based on the lives of 12 people affected by the drug, which was released in 2008. • Josée Lake is a Canadian Paralympic gold medallist swimmer, thalidomide survivor, and president of the Thalidomide Victims Association of Canada • Lorraine Mercer MBE of the United Kingdom, born with phocomelia of both arms and legs, is the only thalidomide survivor to carry the Olympic Torch. • Thomas Quasthoff, an internationally acclaimed bass-baritone, who describes himself: "1.34 meters tall, short arms, seven fingers — four right, three left — large, relatively well-formed head, brown eyes, distinctive lips; profession: singer". • Alvin Law, Canadian motivational speaker and former radio broadcaster.
Change in drug regulations
Thalidomide scandal
The disaster prompted many countries to introduce tougher rules for the testing and licensing of drugs, such as the Kefauver Harris Amendment (US), Directive 65/65/EEC1 (E.U.), and the Medicines Act 1968 (UK). In the United States, the new regulations strengthened the FDA, among other ways, by requiring applicants to prove efficacy and to disclose all side effects encountered in testing. The FDA subsequently initiated the Drug Efficacy Study Implementation to reclassify drugs already on the market.